Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rotem Merose"'
Autor:
Ofer Rotem, Idit Peretz, Michelle Leviov, Iryna Kuchuk, Amit Itay, Margarita Tokar, Shani Paluch-Shimon, Ofra Maimon, Rinat Yerushalmi, Karen Drumea, Ella Evron, Amir Sonnenblick, Einav Gal-Yam, Hadar Goldvaser, Yosef Samih, Rotem Merose, Avital Bareket-Samish, Lior Soussan-Gutman, Salomon M. Stemmer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-8 (2023)
Abstract Data on adjuvant chemotherapy (CT) benefit in ER + HER2‒ early-stage breast cancer (EBC) patients with Recurrence Score (RS) 26-30 are limited. This real-world study evaluated the relationships between the RS, adjuvant treatments, and outc
Externí odkaz:
https://doaj.org/article/ee418dc5761c458bb5099fc02f2cafa0
Autor:
Barliz Waissengrin, Ellie Leidner, Nadav Mishaan, Tamar Safra, Diana Matceyevsky, Ido Laskov, Ido Wolf, Rotem Merose, Talya Levy, Rotem Shayzaf, Dan Grisaru
Publikováno v:
The Oncologist. 26:30-39
Background Conventional first-line combination therapy for ovarian cancer comprises 6 cycles of adjuvant or neoadjuvant carboplatin (AUC5-6) with paclitaxel (175 mg/m2) every 3 weeks (PC-3W). Weekly scheduling of paclitaxel may maximize its antiangio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::888d310e3a93e21f9457fde7c603ee80
https://doi.org/10.1634/theoncologist.2020-0196
https://doi.org/10.1634/theoncologist.2020-0196
Publikováno v:
Harefuah. 161(1)
Geriatric oncology is the clinical field of cancer treatment in older adults (above 65 years) and in the oldest-old (above 80 years). As age is the most significant risk factor for cancer, and with the aging of the population, there is a vast increas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e6ca89b7799d6124fec1e0b7a1d491f7
https://pubmed.ncbi.nlm.nih.gov/35077055
https://pubmed.ncbi.nlm.nih.gov/35077055
Autor:
Ora Rosengarten, Jacob Korach, Phil Stephens, Noa Ben Baruch, Nava Siegelmann-Danieli, Juliann Chmielecki, Lior Soussan-Gutman, Siraj M. Ali, Shulim Shpigel, Jeffrey S. Ross, Zachary R. Chalmers, Julia A. Elvin, Addie Dvir, Rotem Merose, Mario Beiner, Tamar Safra, Vincent A. Miller, Claude Koren, Julia Greenberg
Publikováno v:
Journal of Clinical Oncology. 33:e16578-e16578
e16578 Background: Treatment options for relapsed and refractory metastatic gynecologic malignancies have limited success. Given the scant availability of mechanism-based clinical trials in Israel,...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4959b0e4823bec298f60c3bd1ba29fc9
https://doi.org/10.1200/jco.2015.33.15_suppl.e16578
https://doi.org/10.1200/jco.2015.33.15_suppl.e16578